Three cysteines in human recombinant folylpoly-␥-glutamate synthetase (FPGS) that were reactive with iodoacetamide were located in peptides that were highly conserved across species; the functions of two of these peptides, located in the C-terminal domain, were studied by site-directed mutagenesis. When cDNAs containing mutations in each conserved ionic residue on these peptides were transfected into AUXB1 cells, which lack endogenous FPGS activity, one mutant (D335A) did not complement the auxotrophy, and another (R377A) allowed only minimal growth. FPGS activity could not be detected in insect cells expressing abundant levels of these two mutant proteins from recombinant baculoviruses nor from a virus encoding an H338A mutant FPGS. Kinetic analysis of the purified proteins demonstrated that each of these three mutants was quite different from the others. The major kinetic change detected for the H338A mutation was a 600-fold increase in the K m for glutamic acid. For the D335A mutation, the binding of all three substrates (aminopterin, ATP, and glutamic acid) was affected. For R377A, the K m for glutamic acid was increased by 1500-fold, and there was an Ϸ20-fold decrease in the k cat of the reaction. The binding of the K ؉ ion, a known activator of FPGS, was affected by the D335A and H338A mutations. We conclude that these three amino acids participate in the alignment of glutamic acid in the active site and that Arg-377 is also involved in the mechanism of the reaction.Folates enter mammalian cells as pteroylmonoglutamates, but are rapidly metabolized by the addition of 4 -8 mol of glutamic acid through amide bonds, forming a long ␥-linked side chain. Polyglutamation constitutes a mechanism to trap folates within mammalian cells; the long chain folylpolyglutamates are poorly accepted by the membrane carriers responsible for efflux. The enzyme that catalyzes the synthesis of these polyglutamates, folylpoly-␥-glutamate synthetase (FPGS), 1 is found in both the cytoplasm and the mitochondria of mammalian cells (1, 2); but both species of enzyme are transcribed from the same gene, and the two translated forms differ only by the presence of a leader peptide required for tracking to and penetration of the mitochondria (2). Interestingly, alternate exon usage is not involved in the mechanism whereby the two mRNA species encoding the cytosolic and mitochondrial forms of this enzyme are produced, but rather, alternate transcriptional start sites are used on the same first exon under the control of a TATA-less promoter (2). The study of FPGS has lagged behind the interest in and importance of this enzyme, in large part because of the low levels of enzyme present in even the richest endogenous source. However, with the cloning of the cytosolic (3) and mitochondrial (2) forms of FPGS from human leukemic cells, heterologous expression has allowed access to substantial levels of this protein for the first time. We have presented a preliminary report (4) describing purification of recombinant human leukemic cell cytosolic F...